Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
2.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
3.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
4.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2017 Dec 18;20:73-77. doi: 10.1016/j.msard.2017.12.010. [Epub ahead of print]

PMID:
29324249
5.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
6.

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.

Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M.

Neurology. 2017 Oct 17;89(16):1668-1675. doi: 10.1212/WNL.0000000000004508. Epub 2017 Sep 20.

PMID:
28931645
7.

Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships.

Thormann A, Sørensen PS, Koch-Henriksen N, Thygesen LC, Laursen B, Magyari M.

Eur J Neurol. 2017 Jun;24(6):825-834. doi: 10.1111/ene.13297.

PMID:
28544411
8.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.

Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024.

9.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.

Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.

PMID:
27919501
10.

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort.

Thormann A, Koch-Henriksen N, Laursen B, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2016 Nov;10:181-186. doi: 10.1016/j.msard.2016.10.008. Epub 2016 Oct 29.

PMID:
27919487
11.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Nov;10:169-173. doi: 10.1016/j.msard.2016.10.005. Epub 2016 Oct 26.

PMID:
27919484
12.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
13.

The Danish Multiple Sclerosis Treatment Register.

Magyari M, Koch-Henriksen N, Sørensen PS.

Clin Epidemiol. 2016 Oct 25;8:549-552. eCollection 2016. Review.

14.

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

J Neurol. 2016 Dec;263(12):2484-2493. Epub 2016 Oct 3.

PMID:
27699465
15.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

16.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

17.

Ozanimod: a better or just another S1P receptor modulator?

Sørensen PS.

Lancet Neurol. 2016 Apr;15(4):345-7. doi: 10.1016/S1474-4422(16)00041-7. Epub 2016 Feb 12. No abstract available.

PMID:
26879277
18.

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators.

Eur J Neurol. 2016 May;23(5):861-70. doi: 10.1111/ene.12953. Epub 2016 Feb 5.

PMID:
26848561
19.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Sorensen PS, Blinkenberg M.

Ther Adv Neurol Disord. 2016 Jan;9(1):44-52. doi: 10.1177/1756285615601933. Review.

20.

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium.

J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11.

PMID:
26779831
21.

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.

Dogonowski AM, Blinkenberg M, Paulson OB, Sellebjerg F, Sørensen PS, Siebner HR, Madsen KH.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):912-4. doi: 10.1136/jnnp-2015-311375. Epub 2015 Dec 14. No abstract available.

22.

Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?

Sørensen PS.

Nat Rev Neurol. 2016 Jan;12(1):5-6. doi: 10.1038/nrneurol.2015.224. Epub 2015 Dec 4.

PMID:
26635211
23.

Association between age at onset of multiple sclerosis and vitamin D level-related factors.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Neurology. 2016 Jan 5;86(1):88-93. doi: 10.1212/WNL.0000000000002075. Epub 2015 Oct 7.

PMID:
26446064
24.

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler. 2016 Jun;22(7):926-34. doi: 10.1177/1352458515605908. Epub 2015 Oct 2.

PMID:
26432857
25.

Physical and social environment and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler Relat Disord. 2014 Sep;3(5):600-6. doi: 10.1016/j.msard.2014.07.002. Epub 2014 Jul 21.

PMID:
26265272
26.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G.

Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.

27.

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F.

PLoS One. 2015 Mar 4;10(3):e0118830. doi: 10.1371/journal.pone.0118830. eCollection 2015.

28.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

29.

Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.

Olsson A, Oturai DB, Sørensen PS, Oturai PS, Oturai AB.

Mult Scler. 2015 Oct;21(12):1557-65. doi: 10.1177/1352458514566417. Epub 2015 Jan 26.

PMID:
25623251
30.

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26. Review.

31.

The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.

Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):305-17. doi: 10.1177/1352458514564487. Epub 2015 Jan 12. Review.

32.

Therapeutic interference with leukocyte recirculation in multiple sclerosis.

Sellebjerg F, Sørensen PS.

Eur J Neurol. 2015 Mar;22(3):434-42. doi: 10.1111/ene.12668. Epub 2015 Jan 13. Review.

PMID:
25582213
33.

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.

Marrie RA, Reider N, Stuve O, Trojano M, Sorensen PS, Cutter GR, Reingold SC, Cohen J.

Mult Scler. 2015 Mar;21(3):332-41. doi: 10.1177/1352458514564488. Epub 2014 Dec 23. Review.

34.

A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G.

Mult Scler. 2015 Mar;21(3):294-304. doi: 10.1177/1352458514564489. Epub 2014 Dec 22. Review.

35.

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O.

Mult Scler. 2015 Mar;21(3):342-9. doi: 10.1177/1352458514564486. Epub 2014 Dec 22. Review.

36.

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS.

Mult Scler. 2015 Mar;21(3):318-31. doi: 10.1177/1352458514564485. Epub 2014 Dec 22. Review.

37.

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M.

Mult Scler. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22. Review.

38.

[Fampridine and multiple sclerosis].

Mathiesen HK, Sørensen PS.

Ugeskr Laeger. 2014 Jan 13;176(3A):V06130416. Review. Danish.

PMID:
25347174
39.

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Romme Christensen J, Romme Nielsen B, Sørensen PS, Börnsen L, Sellebjerg F.

J Neuroimmunol. 2014 Nov 15;276(1-2):195-201. doi: 10.1016/j.jneuroim.2014.08.623. Epub 2014 Aug 30.

PMID:
25218212
40.

Gender effects on treatment response to interferon-beta in multiple sclerosis.

Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

Acta Neurol Scand. 2014 Dec;130(6):374-9. doi: 10.1111/ane.12277. Epub 2014 Sep 10.

PMID:
25208455
41.

Prediction of response to interferon therapy in multiple sclerosis.

Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2014 Oct;130(4):268-75. doi: 10.1111/ane.12269. Epub 2014 Jun 18.

PMID:
24943672
42.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

43.

New management algorithms in multiple sclerosis.

Sorensen PS.

Curr Opin Neurol. 2014 Jun;27(3):246-59. doi: 10.1097/WCO.0000000000000096. Review.

PMID:
24759080
44.

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.

Lyksborg M, Siebner HR, Sørensen PS, Blinkenberg M, Parker GJ, Dogonowski AM, Garde E, Larsen R, Dyrby TB.

PLoS One. 2014 Apr 18;9(4):e95540. doi: 10.1371/journal.pone.0095540. eCollection 2014.

45.

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F.

J Neurol. 2014 Jun;261(6):1170-7. doi: 10.1007/s00415-014-7325-8. Epub 2014 Apr 12.

PMID:
24728334
46.

Effects of fingolimod in relapsing-remitting multiple sclerosis.

Sorensen PS.

Lancet Neurol. 2014 Jun;13(6):526-7. doi: 10.1016/S1474-4422(14)70067-5. Epub 2014 Mar 28. No abstract available.

PMID:
24685277
47.

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.

Romme Christensen J, Ratzer R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F.

Neurology. 2014 Apr 29;82(17):1499-507. doi: 10.1212/WNL.0000000000000361. Epub 2014 Mar 28.

PMID:
24682973
48.

Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis.

Wu X, Hanson LG, Skimminge A, Sorensen PS, Paulson OB, Mathiesen HK, Blinkenberg M.

Neurol Res. 2014 Aug;36(8):701-8. doi: 10.1179/1743132813Y.0000000312. Epub 2014 Jan 21.

PMID:
24620975
49.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group.

J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4. Epub 2014 Feb 18.

PMID:
24535134
50.

FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS.

Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, Hasan M, Wu X, Montalban X, Dziegiel MH, Sellebjerg F, Sørensen PS, Helin K, Issazadeh-Navikas S.

Nat Med. 2014 Mar;20(3):272-82. doi: 10.1038/nm.3485. Epub 2014 Feb 16.

PMID:
24531377

Supplemental Content

Loading ...
Support Center